Pathway candidateNCBI-verifiedprotein-coding

CYP4F11

cytochrome P450 family 4 subfamily F member 11

NCBI Gene: 57834 Ensembl GeneCards UniProt: Q9HBI6

Pathway candidate — not linked to PFS or PSSD by any record here

CYP4F11 is in the library because it belongs to the drug metabolism family. No study, report or commentary in the corpus names it, so a variant in CYP4F11 is not, by itself, evidence of anything related to post-drug syndromes.

Gene summary

A protein-coding gene on chromosome 19 (drug metabolism (phase i)). This gene, CYP4F11, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids.

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: Cytochrome P450 4F11
Function (excerpt): A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and their oxygenated derivatives (oxylipins). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Catalyzes with high efficiency the oxidation of the terminal carbon (omega-oxidation) of 3-hydroxy fatty acids, such as 3-hydroxyhexadecanoic and 3-hydroxyoctadecanoic acids, likely participating in the biosynthesis of long-chain 3-hydroxydicarboxylic acids. Omega-hydroxylates and inactivates phylloquinone (vitamin K1), and menaquinone-4 (MK-4, a form of vitamin K2), both acting as cofactors in blood coagulation. Metabolizes with low efficiciency fatty acids, including (5Z,8Z,11Z,14Z)-eicosatetraenoic acid (arachidonate) and its oxygenated metabolite 8-hydroxyeicosatetraenoic acid (8-HETE).
Pathway: Lipid metabolism; arachidonate metabolism. Lipid metabolism; oxylipin biosynthesis. Cofactor degradation; phylloquinone degradation. Xenobiotic degradation.
Subcellular location: Endoplasmic reticulum membrane; Microsome membrane.
Tissue specificity: Expressed mainly in human liver, followed by kidney, heart, and skeletal muscle.

Source: UniProtKB/Swiss-Prot Q9HBI6, release 2026_03, licensed CC BY 4.0. This is the protein’s normal biology, not evidence about post-drug syndromes; associated conditions are inherited disorders of the gene, not PFS, PSSD or PRSD.

Why its pathway is in the library

Phase I enzymes determine exposure to finasteride, SSRIs, and other implicated drugs; variation here shapes the likelihood and persistence of adverse effects.

Written for the whole drug metabolism family, not for CYP4F11 specifically.

Mentioned in 0 corpus records

No corpus record names CYP4F11 directly yet. It is in the library because it sits in a pathway the corpus tracks (Drug metabolism).

Also in drug metabolism (phase i)

All 23 genes

Browse by family on the gene families page.

Gene summary

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: Cytochrome P450 4F11
Function (excerpt): A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and their oxygenated derivatives (oxylipins). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Catalyzes with high efficiency the oxidation of the terminal carbon (omega-oxidation) of 3-hydroxy fatty acids, such as 3-hydroxyhexadecanoic and 3-hydroxyoctadecanoic acids, likely participating in the biosynthesis of long-chain 3-hydroxydicarboxylic acids. Omega-hydroxylates and inactivates phylloquinone (vitamin K1), and menaquinone-4 (MK-4, a form of vitamin K2), both acting as cofactors in blood coagulation. Metabolizes with low efficiciency fatty acids, including (5Z,8Z,11Z,14Z)-eicosatetraenoic acid (arachidonate) and its oxygenated metabolite 8-hydroxyeicosatetraenoic acid (8-HETE).
Pathway: Lipid metabolism; arachidonate metabolism. Lipid metabolism; oxylipin biosynthesis. Cofactor degradation; phylloquinone degradation. Xenobiotic degradation.
Subcellular location: Endoplasmic reticulum membrane; Microsome membrane.
Tissue specificity: Expressed mainly in human liver, followed by kidney, heart, and skeletal muscle.